Patient #33 was 57 years old with a past medical history of type two diabetes mellitus, obesity, and hypertension who presented to the emergency department in acute respiratory failure secondary to Covid19 and in diabetic ketoacidosis. The patient was ventilated on 19Jul2020. Phage therapy was started on 12Oct2020 and was administered over 6 days. During hospitalization and prior to phage therapy, five blood cultures were taken from 19Jul2020 to 10Oct2020 and none were positive for A. baumannii. The 23Jul2020 blood culture was positive for Staph and a blood culture on 14Oct2020 following initiation of phage therapy was positive for E. faecalis. Five sputum cultures from 17Aug2020 to 10Oct2020 were positive for CRAB resistant to all antibiotics but showed intermediate susceptibility to tigecycline. No adverse events were reported as related to phage therapy. The patient expired on 18Oct2020.